What Albon 5% Treats: Main Uses and Benefits

Albon 5% is commonly used to help with the management of Coccidiosis, a protozoal infection in dogs and cats. It is generally applied in clinical settings that involve acute gastrointestinal distress, which may help to address symptom clusters such as distressing manifestations of diarrhea and associated abdominal discomfort that are common symptoms related to systemic imbalance.

The medication is relevant for easing symptoms associated with sulfonamide-susceptible bacterial diseases across multiple organ systems. This is commonly used in conditions that include symptoms related to inflammatory or irritative states in the respiratory tract, the genitourinary tract, and various soft-tissue infections. The therapy is considered relevant in clinical settings marked by acute and disruptive symptom patterns, contributing to easing the overall symptom load and may assist with maintaining functional stability during phases of heightened symptoms.

Quick Fact: Therapeutic Support Domains

Regulatory References

1. official FDA Prescribing Information

The eligibility profile for Albon 5% Oral Suspension is strictly defined by its status as a veterinary drug approved primarily for use in dogs and cats.

Populations and Restrictions

Populations for whom use is allowed are limited to the approved species, primarily dogs and cats. Use in all other animal species is considered non-labeled.

Populations for whom use is contraindicated include humans, as the label bears an absolute WARNING: Not for human use. The medicine must also not be used in animals with a known history of sulfonamide hypersensitivity (allergy) or those with existing marked liver damage or blood dyscrasias.

Condition-Specific Limitations

Conditional eligibility applies to several populations, mandating caution or restricted use. This includes animals that are severely dehydrated or have severe kidney disease (renal impairment). The regulatory label includes a PRECAUTION that animals must maintain adequate water intake during treatment. Use is also restricted and requires caution in pregnant or nursing animals. These eligibility rules are based on the official Prescribing Information established by the FDA.

Interactions with other medicines and products

The official regulatory profile for Sulfadimethoxine (Albon 5%) defines specific interaction patterns structured by their effect on drug levels or therapeutic outcomes.

Pharmacodynamic and Exposure Interactions

Co-administration with certain medicinal products results in clinically significant effects. The combination with Ormetoprim or Trimethoprim is documented as resulting in a synergistic anti-infective effect. Conversely, co-use with Cyclosporine is associated with a formally documented potential for increased risk of kidney disease. Furthermore, Sulfadimethoxine may decrease the plasma concentration of Cyclosporine and may increase the therapeutic efficacy of Glipizide and other Sulfonylurea Agents. Caution is also advised regarding the co-administration of Anticoagulants due to the potential for an increased effect.

Pharmacokinetic and Timing Constraints

Interactions that alter drug absorption are a core focus. Co-administration with Antacids may officially lead to reduced oral absorption of Sulfadimethoxine, which can result in decreased systemic exposure. For this reason, separation may be required between their administrations. There is no mandatory timing restriction documented regarding the use of the drug with food; administration is permitted with or without meals.

Regulatory Restrictions and Considerations

A cross-hypersensitivity risk is officially recognized between the sulfonamide class and certain agents, including Thiazide Diuretics and other Sulfonylurea Agents. The risk of interaction-related adverse effects is officially noted as heightened in patients with pre-existing hepatic or renal impairment due to the potential for altered drug clearance.

Competitive Inhibition of Dihydropteroate Synthase

The action of Sulfadimethoxine is purely mechanistic, exploiting a key difference in microbial metabolism. The drug functions as an antimetabolite, acting as a structural decoy for the natural microbial nutrient, Para-Aminobenzoic Acid ( PABA). Sulfadimethoxine engages in competitive inhibition of the microbial enzyme Dihydropteroate Synthase ( DHPS) , an enzymatic step present only in the microorganism. This molecular blockade interrupts the initial step of the essential Tetrahydrofolate ( THF) Biosynthesis Pathway.

Suppression of Microbial Genetic Synthesis

The physiological consequence results directly from the interrupted THF cascade. Since THF is necessary for synthesizing purine and thymidylate nucleotides—the building blocks for DNA and RNA—the drug creates a critical shortage of genetic material within the pathogen. This deficiency prevents the organism from dividing and multiplying, resulting in a bacteriostatic effect (suppression of proliferation).

Standard instructions for using Albon 5% Oral Suspension (Sulfadimethoxine) define a precise, weight-based administration protocol that is applied to dogs and cats. The approved route for this specific 5% formulation is oral administration. The overall treatment regimen is consistently structured with an initial, higher loading dose designed to rapidly achieve the necessary systemic concentrations, which is then followed by a sustained maintenance dose.

The core dosing schedule is initiated with a single starting dose of 25 mg per pound (55 mg/ kg) of body weight. This is succeeded by a daily maintenance dose of 12.5 mg per pound (27.5 mg/ kg). Due to the drug’s long-acting pharmacological profile, the maintenance dose is administered once daily, specifically every 24 hours thereafter.

For administration, the suspension must be shaken well before using to ensure a homogenous concentration of the active component. The medication can be given with or without food. A critical instruction tied to the proper use of sulfonamides is the necessity of ensuring adequate water intake throughout the entire course of treatment. The duration of use is entirely dependent on clinical response; the established protocol mandates that administration continues until the patient has been asymptomatic for a full 48 hours.

Research evidence / Overview of Studies for Albon 5%

Evidence for Use in Protozoal Infection (Coccidiosis)

Studies of Sulfadimethoxine for Coccidiosis were conducted using Controlled Clinical Trials and Laboratory-Based Challenge Studies submitted to regulatory bodies. These types of studies were used in research exploring how symptoms change over time, and were conducted with both canine (dogs, including puppies) and feline (cats) patients. The specific outcomes researchers examined included measuring the reduction of fecal oocyst counts (a measure of parasite burden) and observing changes in acute clinical symptoms, such as diarrhea.

Findings describe patterns observed in the studies, including reported measurements of oocyst reduction in the studied populations. The evidence derived from these studies contributes to the broader evidence landscape for conditions characterized by fluctuating or episodic manifestations and contributes to the understanding of the labeled use.

Evidence for Use in Sulfonamide-Susceptible Bacterial Infections

Research examined the use of Sulfadimethoxine against certain sulfonamide-susceptible bacterial infections across various organ systems. The available data are derived mainly from Regulatory Efficacy Studies and Microbial Efficacy Tests conducted in laboratory settings. These studies monitored outcomes linked to inflammatory or irritative states and aimed to verify microbial activity against susceptible pathogens.

In clinical contexts, studies observed patterns related to the evolution of acute clinical symptoms during the short-term treatment course for animals with acute infections. The available evidence is structured to meet the requirements for regulatory approval and contributes to the broader evidence landscape relevant to the labeled indications.

Research Gaps and What Remains Uncertain

Research provides context but not individual predictions. The certainty remains low regarding certain aspects of its use due to several limitations. Much of the foundational regulatory evidence is historical, and comparative evidence is lacking for studies that directly compare the medicine to newer treatments now available in clinical settings. Follow-up durations were limited in many studies, meaning that long-term effects are not fully established, and there is limited information for long-term outcomes.

Key Studies & References

1. ALBON- sulfadimethoxine suspension - U.S. National Library of Medicine DailyMed
2. Sodium sulfadimethoxine - Animal Drugs @ FDA (Abbreviated New Animal Drug Application)

Common questions about Albon 5% (FAQ)

Q: What is Albon 5% used for?

A: Albon (sulfadimethoxine) is an antimicrobial agent in the sulfonamide class. It has been studied for its use in treating certain infections caused by susceptible bacteria. It has a long duration of action due to its properties.

Q: How does sulfadimethoxine work?

A: Sulfadimethoxine works by interfering with the synthesis of folic acid within susceptible microorganisms. This mechanism is thought to inhibit the growth and multiplication of the bacteria.

Q: Who should not use sulfadimethoxine?

A: Sulfadimethoxine is generally not used in individuals with a known history of hypersensitivity (allergic reaction) to sulfonamides or trimethoprim. It is also typically avoided in patients with significant liver or kidney dysfunction.

Q: Are there any common side effects?

A: As with many medications, some individuals may experience side effects. Reported side effects associated with sulfadimethoxine have included nausea, vomiting, or headache. More serious, though less common, reactions can involve blood cell changes or skin reactions. If concerning effects are noticed, a healthcare provider should be consulted.

How to Store and Dispose of Albon 5%

The storage and disposal of Albon (sulfadimethoxine) Oral Suspension 5% must comply with specific regulatory requirements to maintain product integrity and ensure public safety.

Official Storage and Handling

Disposal Instructions

Unused or expired Albon 5% must be disposed of in accordance with local, regional, national, and international regulations. Regulatory guidance generally advises against pouring medicine down the sink or toilet. Acceptable household disposal involves mixing the drug with an undesirable substance, sealing it in a bag, and discarding it in the trash, if take-back programs are unavailable.